Adaptimmune Therapeutics Plc ADR’s recent filing unveils that its Chief Medical Officer Norry Elliot unloaded Company’s shares for reported $3243.0 on Jan 17 ’25. In the deal valued at $0.58 per share,5,584 shares were sold. As a result of this transaction, Norry Elliot now holds 7,510 shares worth roughly $1727.3000000000002.
Then, Lunger John sold 5,584 shares, generating $3,243 in total proceeds. Upon selling the shares at $0.58, the Chief Patient Supply Officer now owns 7,510 shares.
Before that, Bertrand William C JR sold 5,584 shares. Adaptimmune Therapeutics Plc ADR shares valued at $3,243 were divested by the Chief Operating Officer at a price of $0.58 per share. As a result of the transaction, Bertrand William C JR now holds 7,510 shares, worth roughly $1727.3000000000002.
Mizuho downgraded its Adaptimmune Therapeutics Plc ADR [ADAP] rating to a Neutral from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Scotiabank began covering ADAP with “Sector outperform” recommendation on May 30, 2024. Bryan Garnier started covering the stock on March 24, 2023. It rated ADAP as “a Buy”.
Price Performance Review of ADAP
On Tuesday, Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] saw its stock fall -3.25% to $0.23. Over the last five days, the stock has lost -8.63%. Adaptimmune Therapeutics Plc ADR shares have fallen nearly -76.36% since the year began. Nevertheless, the stocks have fallen -56.95% over the past one year. While a 52-week high of $1.48 was reached on 01/06/25, a 52-week low of $0.20 was recorded on 04/01/25.
Levels Of Support And Resistance For ADAP Stock
The 24-hour chart illustrates a support level at 0.2255, which if violated will result in even more drops to 0.2190. On the upside, there is a resistance level at 0.2435. A further resistance level may holdings at 0.2550.
How much short interest is there in Adaptimmune Therapeutics Plc ADR?
A steep rise in short interest was recorded in Adaptimmune Therapeutics Plc ADR stocks on 2025-06-13, dropping by -1.27 million shares to a total of 4.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 5.83 million shares. There was a decline of -27.83%, which implies that there is a negative sentiment for the stock.
